PDF(Pubmed)
Abstract：
BACKGROUND: Although antiretroviral therapy (ART) effectively halts disease progression in HIV infection, the complete eradication of the virus remains elusive. Additionally, challenges such as long-term ART toxicity, drug resistance, and the demanding regimen of daily and lifelong adherence required by ART highlight the imperative need for alternative therapeutic and preventative approaches. In recent years, broadly neutralizing antibodies (bNAbs) have emerged as promising candidates, offering potential for therapeutic, preventative, and possibly curative interventions against HIV infection.
OBJECTIVE: This review aims to provide a comprehensive overview of the current state of knowledge regarding the passive immunization of bNAbs in HIV-1-infected individuals.
RESULTS: Recent findings from clinical trials have highlighted the potential of bNAbs in the treatment, prevention, and quest for an HIV-1 cure. While monotherapy with a single bNAb is insufficient in maintaining viral suppression and preventing viral escape, ultimately leading to viral rebound, combination therapy with potent, non-overlapping epitope-targeting bNAbs have demonstrated prolonged viral suppression and delayed time to rebound by effectively restricting the emergence of escape mutations, albeit largely in individuals with bNAb-sensitive strains. Additionally, passive immunization with bNAb has provided a \"proof of concept\" for antibody-mediated prevention against HIV-1 acquisition, although complete prevention has not been obtained. Therefore, further research on the use of bNAbs in HIV-1 treatment and prevention remains imperative.
OBJECTIVE: This review aims to provide a comprehensive overview of the current state of knowledge regarding the passive immunization of bNAbs in HIV-1-infected individuals.
RESULTS: Recent findings from clinical trials have highlighted the potential of bNAbs in the treatment, prevention, and quest for an HIV-1 cure. While monotherapy with a single bNAb is insufficient in maintaining viral suppression and preventing viral escape, ultimately leading to viral rebound, combination therapy with potent, non-overlapping epitope-targeting bNAbs have demonstrated prolonged viral suppression and delayed time to rebound by effectively restricting the emergence of escape mutations, albeit largely in individuals with bNAb-sensitive strains. Additionally, passive immunization with bNAb has provided a \"proof of concept\" for antibody-mediated prevention against HIV-1 acquisition, although complete prevention has not been obtained. Therefore, further research on the use of bNAbs in HIV-1 treatment and prevention remains imperative.
摘要：
背景：尽管抗逆转录病毒疗法（ART）有效地阻止了HIV感染的疾病进展，彻底根除这种病毒仍然遥不可及。此外,诸如长期ART毒性等挑战，耐药性,ART所需的每日和终身依从性的苛刻方案凸显了对替代治疗和预防方法的迫切需要。近年来,广泛中和抗体（bNAb）已经成为有希望的候选物，提供治疗潜力，预防性,以及可能针对艾滋病毒感染的治愈性干预措施。
目的：本综述旨在全面概述HIV-1感染者中bNAb被动免疫的相关知识现状。
结果：临床试验的最新发现强调了bNAb在治疗中的潜力，预防,寻求HIV-1的治疗方法.虽然单一bNAb的单一疗法不足以维持病毒抑制和防止病毒逃逸，最终导致病毒反弹，联合治疗与强效，通过有效限制逃逸突变的出现，非重叠表位靶向bNAb已证明延长的病毒抑制和延迟的反弹时间。尽管主要在具有bNAb敏感菌株的个体中。此外,BNAb的被动免疫为抗体介导的预防HIV-1感染提供了“概念证明”，虽然还没有完全预防。因此,在HIV-1治疗和预防中使用bNAb的进一步研究仍势在必行.
目的：本综述旨在全面概述HIV-1感染者中bNAb被动免疫的相关知识现状。
结果：临床试验的最新发现强调了bNAb在治疗中的潜力，预防,寻求HIV-1的治疗方法.虽然单一bNAb的单一疗法不足以维持病毒抑制和防止病毒逃逸，最终导致病毒反弹，联合治疗与强效，通过有效限制逃逸突变的出现，非重叠表位靶向bNAb已证明延长的病毒抑制和延迟的反弹时间。尽管主要在具有bNAb敏感菌株的个体中。此外,BNAb的被动免疫为抗体介导的预防HIV-1感染提供了“概念证明”，虽然还没有完全预防。因此,在HIV-1治疗和预防中使用bNAb的进一步研究仍势在必行.
